A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

NCT07059299 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Esophagogastric Junction Adenocarcinoma
Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Resectable Esophagogastric Adenocarcinoma
Neoadjuvant Therapy

Interventions

DRUG: Tislelizumab
DRUG: FLOT Chemotherapy

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]
[object Object]